Overview: lions and COVID-19 testing
SARS-CoV-2 infections in lions are biologically plausible because lions are susceptible to the virus and can show respiratory signs. COVID-19 tests developed for humans can sometimes be used in lions under professional oversight, but assays are not always validated for this species and results must be interpreted carefully. Testing in lions is typically considered in specific situations such as known exposure, outbreaks in nearby facilities, or before movement to vulnerable settings. This overview explains when testing may be useful, which sample types and methods apply, how results should be interpreted, and what biosecurity measures remain essential regardless of test outcomes.
When testing lions may be considered
Testing is not routine for lions and is usually reserved for particular risk-based scenarios. Decision-making should involve veterinary professionals and, when relevant, public health or wildlife health partners.
- Known or suspected contact with a person or animal confirmed or suspected to have COVID-19.
- Respiratory illness clusters consistent with SARS-CoV-2 in a group or facility.
- Pre-movement screening for facilities caring for high-risk individuals (e.g., immunocompromised staff or animals).
- Investigation of unusual mortality or morbidity where COVID-19 is on the differential list.
Key contexts where testing might be discussed
- Outbreaks in proximate animal populations or human staff.
- Facilities with mixed species, including felids and primates, where cross-species transmission is plausible.
- Institutions that routinely test higher-risk species and seek a uniform approach.
Sample types and collection considerations
Sample collection from lions should only be performed by trained personnel using appropriate safety protocols. The suitability of sample types depends on the test platform and the clinical question.
| Sample type | Typical use | Collection considerations |
|---|---|---|
| Nasopharyngeal or nasal swab | Most common for PCR and some rapid antigen tests | May require sedation; must use appropriate swabs and viral transport medium if specified by the assay |
| Oropharyngeal swab | Alternative or adjunct in some protocols | Less sensitive than nasopharyngeal in some studies; technique-dependent |
| Fecal sample | Detection of viral RNA; limited interpretation value | Can indicate shedding but not necessarily active infection requiring clinical correlation |
| Serum or plasma | Antibody (serologic) testing | Useful for retrospective or epidemiologic studies; not ideal for acute diagnosis |
Test types and their application in lions
Three broad categories of tests are available, each with strengths and limitations when considered for lions.
Nucleic acid amplification tests (NAATs), such as PCR
NAATs detect viral genetic material and are generally more sensitive and less prone to cross-reactivity than antigen tests. They are often the preferred method when accuracy is critical and turnaround time is acceptable. Pooled samples are possible but must be validated for the species and assay. In lions, false negatives can occur due to timing relative to infection, sample quality, or inadequate swabbing.
Antigen tests (rapid diagnostic tests)
Antigen tests offer faster results and are useful in outbreak settings for rapid triage. They are generally less sensitive than NAATs, especially when viral loads are low, and are more likely to yield false negatives. Positive results in lions should typically be confirmed with a NAAT if critical decisions depend on them.
Serologic (antibody) testing
Antibody tests are not reliable for diagnosing acute infection and can misinterpret recent versus past exposure. They are most useful for population-level studies rather than individual clinical decisions. Interpretation in lions should account with species-specific validation data when available.
Interpreting results and reporting
A positive test in a lion should be considered in context of clinical signs, epidemiologic links, and local prevalence. A negative test does not definitively exclude infection, particularly if pre-test probability is high or sampling was suboptimal. Laboratories should confirm methods used and indicate whether the assay is validated for felids; if not, results may be considered preliminary and require cautious interpretation. Reporting should include sample type, test platform, and any limitations noted by the laboratory.
Biosecurity and risk management beyond testing
Testing is one component of a broader risk-management strategy. Even with negative test results, facilities should maintain biosecurity measures tailored to the setting.
- Separate housing or cohorting for new or potentially infectious individuals.
- Use of personal protective equipment (PPE) and hygiene protocols during animal care and sampling.
- Ventilation and outdoor access management where practical.
- Staggered routines to reduce cross-animal contact during high-risk periods.
- Clear communication with staff and stakeholders about procedures and expectations.
Limitations, uncertainties, and practical notes
No test is perfect, and using tests in species for which they are not officially validated introduces additional uncertainty. Sensitivity, specificity, and practical factors such as animal restraint requirements and staff safety must all be weighed. Close collaboration with veterinary diagnostic laboratories and wildlife health experts can improve decision quality. Facilities should document the rationale for testing, methods used, and follow-up actions to support learning and future planning.
Summary and key takeaways
Testing lions for SARS-CoV-2 can be helpful in defined exposure or outbreak situations but is not a substitute for robust biosecurity. NAATs are generally preferred for diagnosis, while antigen tests can support rapid triage. Results require careful contextual interpretation, and negative tests do not eliminate risk. Ongoing communication with veterinary professionals, clear protocols, and practical safeguards remain central to protecting both animal and human health.